Oppenheimer analyst Jay Olson maintained a Buy rating on Relmada Therapeutics (RLMD) yesterday and set a price target of $75.00. The company’s shares closed last Monday at $33.22.
According to TipRanks.com, Olson is a 1-star analyst with an average return of -0.6% and a 42.5% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Relmada Therapeutics with a $57.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $54.00 and a one-year low of $23.25. Currently, Relmada Therapeutics has an average volume of 91.13K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.
